JY
KROS icon

Jeff Yass’s Keros Therapeutics KROS Stock Holding History

Jeff Yass’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
21,043
+9,801
+87% +$109K ﹤0.01% 11691
2026
Q1 		$124K Sell
11,242
-2,147
-16% -$33.2K ﹤0.01% 12192
2025
Q4 		$273K Sell
13,389
-203,311
-94% -$3.57M ﹤0.01% 10172
2025
Q3 		$3.43M Buy
216,700
+103,035
+91% +$1.52M ﹤0.01% 4725
2025
Q2 		$1.52M Sell
113,665
-8,184
-7% -$110K ﹤0.01% 6412
2025
Q1 		$1.24M Sell
121,849
-89,460
-42% -$1.04M ﹤0.01% 6710
2024
Q4 		$3.35M Buy
211,309
+202,261
+2,235% +$10.5M ﹤0.01% 4260
2024
Q3 		$525K Buy
9,048
+666
+8% +$32.9K ﹤0.01% 8350
2024
Q2 		$383K Sell
8,382
-7,043
-46% -$378K ﹤0.01% 8897
2024
Q1 		$1.02M Sell
15,425
-107
-0.7% -$6.34K ﹤0.01% 6867
2023
Q4 		$618K Buy
+15,532
New +$487K ﹤0.01% 8150
2023
Q3 		– Sell
-8,770
Closed -$352K – 12511
2023
Q2 		$352K Sell
8,770
-17,783
-67% -$780K ﹤0.01% 9109
2023
Q1 		$1.13M Buy
26,553
+18,546
+232% +$937K ﹤0.01% 6485
2022
Q4 		$384K Sell
8,007
-28,015
-78% -$1.31M ﹤0.01% 8483
2022
Q3 		$1.35M Buy
+36,022
New +$1.25M ﹤0.01% 5848
2022
Q2 		– Sell
-20,045
Closed -$1.09M – 13459
2022
Q1 		$1.09M Buy
20,045
+2,712
+16% +$139K ﹤0.01% 6885
2021
Q4 		$1.01M Buy
17,333
+4,380
+34% +$218K ﹤0.01% 7255
2021
Q3 		$512K Buy
12,953
+4,230
+48% +$151K ﹤0.01% 9343
2021
Q2 		$370K Buy
+8,723
New +$473K ﹤0.01% 10319
2021
Q1 		– Sell
-6,398
Closed -$451K – 12554
2020
Q4 		$451K Buy
+6,398
New +$403K ﹤0.01% 8508

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jeff Yass's KROS Position: Q2 2026 in Review

Jeff Yass increased its Keros Therapeutics (KROS) stake by 87% in Q2 2026, buying an estimated $109K and bringing the position to 21,043 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #11691.

Jeff Yass first reported a position in KROS in Q4 2020 and has held it in 20 quarters since. The position peaked at $3.43M in Q3 2025. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Jeff Yass held 21,043 shares of Keros Therapeutics worth $225K as of Q2 2026.
  • Jeff Yass bought 9,801 Keros Therapeutics shares in Q2 2026, an estimated $109K.
  • Keros Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11691 holding.
  • Jeff Yass first reported a position in Keros Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Jeff Yass's Keros Therapeutics position peaked at $3.43M in Q3 2025.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.